Still no news nor progress has been made on the discussions regarding reimbursement of combination therapies using SGLT-2 inhibitors.

After a long three years, the Health Insurance Review and Assessment Service called for a diabetes expert meeting to discuss expanding reimbursement of SGLTL-2 inhibitors in September last year. At the meeting, the experts saw consensus on integrating and accepting the ‘class effect’ of DPP-4 and SGLT-2 inhibitor combinations as well as three-drug combinations for reimbursement. Such results had sparked hope that the non-reimbursed combination drugs would also be finally listed for reimbursement.

But that was the last spark of hope. The year has passed a